ArticleMedical hypotheses2020
Premises among SARS-CoV-2, dysbiosis and diarrhea: Walking through the ACE2/mTOR/autophagy route.
Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 38 citations in OpenAlex.
- Preventing ventilator-associated pneumonia via the gut-lung axis: the Shenling Baizhu San hypothesis.Frontiers in medicine · 2026Article
- Translating animal models of SARS-CoV-2 infection to vascular, neurological and gastrointestinal manifestations of COVID-19.Disease models & mechanisms · 2025Review
- Chronic inflammation in post-acute sequelae of COVID-19 modulates gut microbiome: a review of literature on COVID-19 sequelae and gut dysbiosis.Molecular medicine (Cambridge, Mass.) · 2025Review
- Symptom clusters and symptom networks of symptom experiences in patients with SARS-CoV-2 infection.Heliyon · 2024Article
- ACE2 mediates tryptophan alleviation on diarrhea by repairing intestine barrier involved mTOR pathway.Cellular & molecular biology letters · 2024Article
- Potential Beneficial Effects of Naringin and Naringenin on Long COVID-A Review of the Literature.Microorganisms · 2024Review
- Integrated analysis of gut microbiome and its metabolites in ACE2-knockout and ACE2-overexpressed mice.Frontiers in cellular and infection microbiology · 2024Article
- Impact of SARS-CoV2 infection on gut microbiota dysbiosis.Microbiome research reports · 2024Review
- Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockade.Emerging microbes & infections · 2023Article
- Review
- Combined Analysis of the Whole Transcriptome of Piglets Infected with SADS-CoV Virulent and Avirulent Strains.Microorganisms · 2023Article
- Pathogenesis and Mechanisms of SARS-CoV-2 Infection in the Intestine, Liver, and Pancreas.Cells · 2023Review
- The relationship between gut microbiota and COVID-19 progression: new insights into immunopathogenesis and treatment.Frontiers in immunology · 2023Review
- Autoimmune Hemolytic Anemia: A Late Presentation of Post-COVID-19 Syndrome.Oman medical journal · 2023Article
- Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential.World journal of gastroenterology · 2022Review
- Direct, indirect, post-infection damages induced by coronavirus in the human body: an overview.Virusdisease · 2022Review
- SARS-CoV-2-associated gut microbiome alteration; A new contributor to colorectal cancer pathogenesis.Pathology, research and practice · 2022Review
- Role of Micronutrients and Gut Microbiota-Derived Metabolites in COVID-19 Recovery.International journal of molecular sciences · 2022Review
- Gut Microbiota and COVID-19: Potential Implications for Disease Severity.Pathogens (Basel, Switzerland) · 2022Review
- SARS-CoV-2 causes secretory diarrhea with an enterotoxin-like mechanism, which is reduced by diosmectite.Heliyon · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, a new coronavirus (SARS-CoV-2) was discovered in China. Due to its high level of contagion, it has already reached most countries, quickly becoming a pandemic. Although the most common symptoms are related to breathing problems, SARS-CoV-2 infections also affect the gastrointestinal tract culminating in inflammation and diarrhea. However, the mechanisms related to these enteric manifestations are still not well understood. Evidence shows that the SARS-CoV-2 binds to the angiotensin-converting enzyme receptor 2 (ACE2) in host cells as a viral invasion mechanism and can infect the lungs and the gut. Other viruses have already been linked to intestinal symptoms through binding to ACE2. In turn, this medical hypothesis article conjectures that the ACE2 downregulation caused by the SARS-CoV-2 internalization could lead to decreased activation of the mechanistic target of mTOR with increased autophagy and lead to intestinal dysbiosis, resulting in diarrhea. Besides that, dysbiosis can directly affect the respiratory system through the lungs. Although there are clues to other viruses that modulate the ACE2/gut/lungs axis, including the participation of autophagy and dysbiosis in the development of gastrointestinal symptoms, there is still no evidence of the ACE2/mTOR/autophagy pathway in SARS-CoV-2 infections. Thus, we propose that the new coronavirus causes a change in the intestinal microbiota, which culminates in a diarrheal process through the ACE2/mTOR/autophagy pathway into enterocytes. Our assumption is supported by premises that unregulated intestinal microbiota increases the susceptibility to other diseases and extra-intestinal manifestations, which can even cause remote damage in lungs. These putative connections lead us to suggest and encourage future studies aiming at assessing the aforementioned hypothesis and regulating dysbiosis caused by SARS-CoV-2 infection, in order to confirm the decrease in lung injuries and the improvement in the prognosis of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.